Mangoceuticals, Inc. (NASDAQ:MGRX) Short Interest Update

Mangoceuticals, Inc. (NASDAQ:MGRX) was the target of a large drop in short interest in April. As of April 30th, there was short interest totaling 451,464 shares, a drop of 51.3% from the April 15th total of 926,613 shares. Currently, 3.2% of the shares of the stock are sold short. Based on an average daily volume of 563,464 shares, the days-to-cover ratio is currently 0.8 days.

Mangoceuticals Stock Performance

MGRX opened at $0.44 on Monday. The stock has a market capitalization of $7.47 million, a PE ratio of -0.17 and a beta of 2.12. Mangoceuticals has a 1-year low of $0.16 and a 1-year high of $2.75. The firm has a 50-day moving average price of $0.38 and a two-hundred day moving average price of $0.73.

Mangoceuticals (NASDAQ:MGRX) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $0.09 million during the quarter. Mangoceuticals had a negative net margin of 4,536.70% and a negative return on equity of 109.38%.

Institutional Investors Weigh In On Mangoceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in Mangoceuticals in the 4th quarter valued at about $25,000. Boothbay Fund Management LLC acquired a new stake in Mangoceuticals in the 4th quarter valued at about $28,000. Jane Street Group LLC acquired a new stake in Mangoceuticals in the 4th quarter valued at about $35,000. Geode Capital Management LLC increased its position in Mangoceuticals by 35.4% in the 2nd quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock valued at $40,000 after acquiring an additional 6,928 shares in the last quarter. Finally, Ikarian Capital LLC acquired a new stake in Mangoceuticals in the 4th quarter valued at about $102,000. Institutional investors and hedge funds own 56.72% of the company’s stock.

Wall Street Analysts Forecast Growth

MGRX has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Mangoceuticals to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mangoceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.